Phase 2 N=25 Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke
Stroke
Primary: Change in Action Research Arm Test Score From Baseline to 3 Months — 23.5; 24; 15.1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Nausea With Vomiting Chemotherapy-Induced
Primary: Complete Acute Response — 4; 4; 3 Participants
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 2 N=30 Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Glioblastoma, Adult
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 2 Participants
Phase 2 N=10 A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Procedure and/or Product Related Adverse Events — 70.0; 60.0; 30.0; 20.0 percent of participants
Phase 2 N=57 The Effect of Cannabidiol in Learning and Memory of Adults
Memory
Primary: Sum of Trials (I-V) — 49.09; 47.17 score on a scale
Phase 2 N=73 Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
Lung Cancer
Primary: Efficacy of Pembrolizumab Re-challenge Measured by Overall Survival — 9.4; 19.1 months — p=0.016
Phase 2 N=22 Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Phase 2 N=78 Beta-glucan and Immune Response to Influenza Vaccine
Healthy Aging
Primary: Antibody Titer — 127; 143; 241; 160 Titer
Phase 2 N=10 Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer · Lung Cancer Stage III
Primary: 12-Month Progression-free Survival (PFS) Time — 208 days
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
Phase 2 N=255 Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis With Liver Fibrosis
Primary: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by…
Phase 2 N=6 Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Huntington Disease · Chorea
Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27
Phase 2 N=9 Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
Schizophrenia Spectrum and Other Psychotic Disorders · Treatment-resistant Schizophrenia
Primary: Positive and Negative Syndrome Scale (PANSS) — 72.9 score on a scale
Phase 2 N=54 Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
Tuberculosis · HIV
Primary: Percentage of Participants With Adverse Events of ≥ Grade 3 Severity — 38.9; 11.1; 83.3 percentage of participants